Reply: Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy

Biomed J. 2022 Oct;45(5):849-850. doi: 10.1016/j.bj.2022.01.012. Epub 2022 Jan 19.
No abstract available

Keywords: CA-125; HIPEC; Hyperthermic intraperitoneal chemotherapy; Ovarian cancer; Renal failure.

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Hyperthermic Intraperitoneal Chemotherapy*